NVCR Stock Analysis: Buy, Sell, or Hold?
NVCR - NovoCure Limited Ordinary Shares
$13.61
-0.67 (-4.69%)
▼
5d:
-23.45%
30d:
-23.32%
90d:
+15.24%
WAIT
LOW Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 23, 2026
29d
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When NVCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NVCR is down 23.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NVCR is down 23.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NVCR is currently trading at $13.61, which is considered oversold relative to its 30-day fair value range of $16.00 to $18.16.
Technical Outlook: Technically, NVCR is in a strong downtrend. The price is currently testing key support at $13.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.00 (+91.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVCR is in a strong downtrend. The price is currently testing key support at $13.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.00 (+91.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$16.00 -
$18.16
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding NVCR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 91.0% below Wall St target ($26.00)
- WARNING: Recommendation downgraded due to -23.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$16.00 -
$18.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.56
Resistance Level
$18.35
Current Trend
Strong Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.41
Wall Street Target
$26.00
(+91.0%)
Revenue Growth (YoY)
12.3%
Earnings Growth (YoY)
-6.0%
Profit Margin
-25.7%
Share & Embed Analysis
Last updated: June 23, 2026 2:24 AM ET
Data refreshes hourly during market hours. Next update: 3:24 AM
Data refreshes hourly during market hours. Next update: 3:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Mukund Paravasthu
SELL
43246 shares
2026-03-05
Christoph Brackmann
SELL
6412 shares
2026-03-04
Frank X Leonard
SELL
5607 shares
2026-03-04
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 57 HOLD |
Advanced NVCR Option Strategies
Professional options setups generated by AI based on today's NVCR price and gamma walls.
